Table 1.
Characteristics of 225 (alemtuzumab) and 205 (basiliximab) recipients and solitary kidney transplants.
| Characteristic | Alemtuzumab (n = 225) | Basiliximab (n = 205) | p value |
|---|---|---|---|
| Male gender (n, %) | 140 (62.22%) | 136 (66.34%) | 0.495 |
| Age in years (mean ± SD) | 48.46 ± 12.37 | 59.57 ± 13.16 | <0.0001 |
| Cause of renal failure (n, %) | |||
| Glomerulonephritis | 71 (31.55%) | 68 (33.17%) | 0.533 |
| Diabetes mellitus | 61 (27.12%) | 58 (28.29%) | 0.512 |
| Polycystic kidney disease | 22 (9.78%) | 23 (11.22%) | 0.856 |
| Others | 71 (31.55%) | 59 (28.78%) | 0.051 |
| prior kidney transplantation (n, %) | 41 (18.22%) | 17 (8.29%) | 0.002 |
| PRA+ recipients (n, %) | 143 (63.56%) | 131 (63.90%) | 0.021 |
| PRA at KTx (in %, mean ± SD) | 22.93 ± 26.99 | 15.65 ± 4.25 | 0.189 |
| HLA-A mismatch | 148 (65.78%) | 152 (74.14%) | 0.199 |
| HLA-B mismatch | 180 (80%) | 172 (83.90%) | 0.019 |
| HLA-DR mismatch | 169 (75.11%) | 166 (80.97%) | 0.457 |
| CMV-IgG+ (n, %) | 141 (62.67%) | 145 (70.73%) | 0.135 |
| CMV mismatch (R−/D+) (n, %) | 42 (18.67%) | 34 (16.59%) | 0.061 |
| Lymphocyte count before Tx (in %, mean ± SD) | 22.8 ± 9.41 | 23.77 ± 10.42 | 0.412 |